We are live on ! Find out more
CGEM icon

Cullinan Therapeutics

103 hedge funds and large institutions have $330M invested in Cullinan Therapeutics in 2023 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 31 increasing their positions, 34 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

93% more call options, than puts

Call options by funds: $29K | Put options by funds: $15K

55% more first-time investments, than exits

New positions opened: 17 | Existing positions closed: 11

6% more funds holding

Funds holding: 97 → 103 (+6)

0.47% less ownership

Funds ownership: 82.37% → 81.9% (-0.47%)

9% less repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 34

25% less funds holding in top 10

Funds holding in top 10: 4 → 3 (-1)

80% less capital inflows, than outflows

Capital inflows: $14.9M | Capital outflows: $75.2M

Holders
103
Holders Change
+6
Holders Change %
+6.19%
% of All Funds
1.64%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.05%
New
17
Increased
31
Reduced
34
Closed
11
Calls
$29​K
Puts
$15​K
Net Calls
+$14​K
Net Calls Change
+$4​K

CGEM Hedge Fund Activity: Q1 2023 in Review

103 of the 6,286 institutional investors tracked by Wall St. Rank reported a position in Cullinan Therapeutics (CGEM) for Q1 2023, worth a combined $330M — down 17% from $398M a quarter earlier.

Buyers outnumbered sellers: 17 funds opened new CGEM positions and 11 closed out — a net gain of 6 holders — while 31 added to existing stakes and 34 trimmed.

The largest buyer was Citadel Advisors, adding an estimated $4.17M. The largest seller was BVF Inc, cutting an estimated $47.5M.

  • 103 institutional investors held Cullinan Therapeutics (CGEM) as of Q1 2023, up from 97 in Q4 2022.
  • Funds reported $330M of Cullinan Therapeutics stock for Q1 2023, down 17% quarter-over-quarter.
  • 17 funds opened new Cullinan Therapeutics positions in Q1 2023 and 11 closed out, a net change of +6 holders.
  • The largest Cullinan Therapeutics buyer in Q1 2023 was Citadel Advisors, an estimated $4.17M added.
  • The largest Cullinan Therapeutics seller in Q1 2023 was BVF Inc, an estimated $47.5M sold.

Based on aggregated 13F filings for Q1 2023.